Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1803-1811

  Graça, Inês ^a,b,d   Sousa, Elsa J ^a,b   Baptista, Tiago ^a,b   Almeida, Mafalda ^a,b   Ramalho Carvalho, João ^a,b   Palmeira, Carlos ^a   Henrique, Rui ^a,c,e   Jerónimo, Carmen ^a,b,e  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b Departments of Genetics   (Portugal)

^c Departments of Pathology   (Portugal)

^d POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

Apoptosis; DNA methyltransferases; Proliferation; Prostate cancer; RG108

Indexed keywords

APC PROTEIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; GLUTATHIONE TRANSFERASE P1; MESSENGER RNA; N PHTHALOYLTRYPTOPHAN; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA 2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA (CYTOSINE 5) METHYLTRANSFERASE; PHTHALIMIDE DERIVATIVE; TRYPTOPHAN;

22RV1 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ASSAY; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; DNA METHYLATION; DOSE RESPONSE; DU145 CELL LINE; ENZYME ACTIVITY; GENE ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; LNCAP CELL LINE; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; METABOLISM; PATHOLOGY; PROMOTER REGION; PROSTATIC NEOPLASMS; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; PHTHALIMIDES; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRYPTOPHAN;

EID: 84903700216     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990516     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer J Clinicians 2012; 62(1): 10-29.
2. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clinic proceedings Mayo Clinic 2010; 85(1): 77-86.
3. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Development 2010; 24(18): 1967-2000.
4. Jeronimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer. Clinical cancer research: an official J Am Assoc Cancer Res 2004; 10(24): 8472-8.
5. Henrique R, Costa VL, Cerveira N, et al. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med 2006; 84(11): 911-8.
6. Jeronimo C, Henrique R, Hoque MO, et al. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clinical cancer research: an official J Am Assoc Cancer Res 2004; 10(12 Pt 1): 4010-4.
7. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005; 97(20): 1498-506.
8. Thibault A, Figg WD, Bergan RC, et al. A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 1998; 84(1): 87-9.
9. McCabe MT, Low JA, Daignault S, et al. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 2006; 66(1): 385-92.
10. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91(25): 11797-801.
11. Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005; 65(14): 6305-11.
12. Bardenheuer W, Lehmberg K, Rattmann I, et al. Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia: official J Leukemia Soc Am, Leukemia Res Fund, UK 2005; 19(12): 2281-8.
13. Pearson H, Stirling D. DNA extraction from tissue. Methods Mol Biol 2003; 226: 33-4.
14. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a highthroughput assay to measure DNA methylation. Nucleic acids Res 2000; 28(8): E32.
15. Nakabayashi M, Sartor O, Jacobus S, et al. Response to docetaxel/carboplatin-based chemotherapy as first-and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU international 2008; 101(3): 308-12.
16. Galsky MD, Small AC, Tsao CK, Oh WK. Clinical development of novel therapeutics for castration-resistant prostate cancer: Historic Challenges and Recent Successes. CA: a Cancer J Clinicians 2012.
17. Jeronimo C, Bastian PJ, Bjartell A, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60(4): 753-66.
18. Mishra MV, Bisht KS, Sun L, et al. DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Molecular cancer research: MCR 2008; 6(2): 243-9.
19. Abdulhaq H, Rossetti JM. The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opinion Investigational Drugs 2007; 16(12): 1967-75.
20. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J clinical oncology: official J Am Soc Clin Oncol 2007; 25(29): 4603-9.
21. Bauman J, Verschraegen C, Belinsky S, et al. A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Cancer Chemotherapy Pharmacol 2012; 69(2): 547-54.
22. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. The oncologist 2005; 10(3): 176-82.
23. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20(1): 85-93.
24. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106(8): 1794-803.
25. Festuccia C, Gravina GL, D'Alessandro AM, et al. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocrine-Related Cancer 2009; 16(2): 401-13.
26. Gravina GL, Festuccia C, Millimaggi D, et al. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. The Prostate 2008; 68(7): 793-801.
27. Festuccia C, Gravina GL, Biordi L, et al. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. The Prostate 2009; 69(14): 1529-37.
28. Pulukuri SM, Rao JS. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces proapoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol 2005; 26(4): 863-71.
29. Bott SR, Arya M, Kirby RS, Williamson M. p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation. Prostate Cancer Prostatic Diseases 2005; 8(4): 321-6.
30. Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PloS one 2011; 6(9): e25634.
31. Gabbara S, Bhagwat AS. The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochemical J 1995; 307 (Pt 1): 87-92.
32. Gravina GL, Marampon F, Di Staso M, et al. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. The Prostate 2010; 70(11): 1166-78.
33. Gravina GL, Marampon F, Piccolella M, et al. Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology 2011; 152(12): 4550-61.